双SGLT1/2抑制剂索格列净治疗1型糖尿病的疗效与安全性:随机对照试验的荟萃分析
该荟萃分析纳入6项随机安慰剂对照试验(n=3238,疗程4-52周),评估索格列净在18岁以上1型糖尿病患者中的疗效与安全性。索格列净降低HbA1c(加权均数差-0.34%,95%CI -0.41%至-0.27%,P<0.001)、空腹及餐后2小时血糖、每日总/基础/餐时胰岛素剂量,改善目标范围内时间(+9.73%,95%CI 6.66%至12.81%)并降低体重、收缩压和尿白蛋白。索格列净减少低血糖(-9.09事件/患者年)和严重低血糖(RR 0.69,95%CI 0.49至0.98),但增加酮症酸中毒(RR 3.93,95%CI 1.94至7.96)、生殖道感染(RR 3.12)、腹泻(RR 1.50)和容量不足事件(RR 2.19)。初始HbA1c和基础胰岛素剂量调整与酮症酸中毒风险相关;400 mg/日剂量在多数结局上优于200 mg/日且不增加不良事件风险。
要点
- 索格列净降低HbA1c 0.34%(95%CI -0.41%至-0.27%,P<0.001),并减少每日总胰岛素剂量8.99%、基础胰岛素8.03%、餐时胰岛素9.14%。
- 索格列净增加酮症酸中毒风险(RR 3.93,95%CI 1.94至7.96),初始HbA1c和基础胰岛素剂量调整与酮症酸中毒风险相关。
- 索格列净减少严重低血糖(RR 0.69,95%CI 0.49至0.98)和低血糖事件(-9.09事件/患者年,95%CI -13.82至-4.36)。
- 索格列净400 mg/日剂量在多数血糖及非血糖结局上优于200 mg/日,且不增加不良事件风险。
- 索格列净还增加生殖道感染(RR 3.12)、腹泻(RR 1.50)和容量不足事件(RR 2.19)风险。
适用人群与场景
- 18岁以上的1型糖尿病患者,纳入6项随机安慰剂对照试验,疗程4-52周。
处置流程与药物剂量
- 索格列净400 mg/日剂量在多数血糖及非血糖结局上优于200 mg/日剂量,且不增加不良事件风险。
- 初始HbA1c和基础胰岛素剂量调整与酮症酸中毒风险相关;作者认为通过合适患者选择和基础胰岛素下调可最小化酮症酸中毒风险。
红旗征与不能漏的情况
- 酮症酸中毒风险增加(RR 3.93,95%CI 1.94至7.96),初始HbA1c和基础胰岛素剂量调整与酮症酸中毒风险相关。
- 容量不足事件风险增加(RR 2.19,95%CI 1.10至4.36)。
- 生殖道感染风险增加(RR 3.12,95%CI 2.14至4.54)。
- 腹泻风险增加(RR 1.50,95%CI 1.08至2.10)。
研究设计与关键结果
- 研究设计:随机对照试验的荟萃分析,纳入6项随机安慰剂对照试验(n=3238,疗程4-52周),对象为18岁以上1型糖尿病患者。
- HbA1c:加权均数差-0.34%(95%CI -0.41%至-0.27%,P<0.001)。
- 空腹血糖:加权均数差-16.98 mg/dL(95%CI -22.1至-11.9);餐后2小时血糖:-39.2 mg/dL(95%CI -50.4至-28.1)。
- 每日总胰岛素剂量:-8.99%(95%CI -10.93%至-7.05%);基础胰岛素:-8.03%(95%CI -10.14%至-5.93%);餐时胰岛素:-9.14%(95%CI -12.17%至-6.12%)。
- 目标范围内时间:加权均数差+9.73%(95%CI 6.66%至12.81%);体重:-3.54%(95%CI -3.98%至-3.09%);收缩压:-3.85 mmHg(95%CI -4.76至-2.93);尿白蛋白/肌酐比值:-14.57 mg/g(95%CI -26.87至-2.28)。
- 低血糖:加权均数差-9.09事件/患者年(95%CI -13.82至-4.36);严重低血糖:RR 0.69(95%CI 0.49至0.98)。
- 不良事件:酮症酸中毒RR 3.93(95%CI 1.94至7.96);生殖道感染RR 3.12(95%CI 2.14至4.54);腹泻RR 1.50(95%CI 1.08至2.10);容量不足事件RR 2.19(95%CI 1.10至4.36)。
- 剂量比较:索格列净400 mg/日剂量在多数血糖及非血糖结局上优于200 mg/日剂量,且不增加不良事件风险。
证据类型、等级与局限
- 证据类型:随机对照试验的荟萃分析,采用GRADE方法评估证据强度。
- 大多数结局的证据质量高至中等,但主要不良心血管事件和全因死亡的证据质量低。
- 局限:试验疗程相对较短,无法评估长期结局。
对床旁实践的改变
- 索格列净可改善1型糖尿病患者的血糖及非血糖结局并减少低血糖,但需警惕酮症酸中毒、生殖道感染、腹泻和容量不足事件风险。
- 作者认为通过合适患者选择和基础胰岛素剂量下调可最小化酮症酸中毒风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the efficacy and safety of dual sodium glucose cotransporter (SGLT) 1/2 inhibitor sotagliflozin in type 1 diabetes mellitus.
DESIGN: Meta-analysis of randomised controlled trials.
DATA SOURCES: Medline; Cochrane Library; Embase; international meeting abstracts; international and national clinical trial registries; and websites of US, European, and Japanese regulatory authorities, up to 10 January 2019.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials evaluating the effect of sotagliflozin versus active comparators or placebo on glycaemic and non-glycaemic outcomes and on adverse events in type 1 diabetes in participants older than 18. Three reviewers extracted data for study characteristics, outcomes of interest, and risk of bias and summarised strength of evidence using the grading of recommendations assessment, development, and evaluation approach. Main outcomes were pooled using random effects models.
RESULTS: Of 739 records identified, six randomised placebo controlled trials (n=3238, duration 4-52 weeks) were included. Sotagliflozin reduced levels of glycated haemoglobin (HbA1c; weighted mean difference -0.34% (95% confidence interval -0.41% to -0.27%), P<0.001); fasting plasma glucose (-16.98 mg/dL, -22.1 to -11.9; 1 mg/dL=0.0555 mmol/L) and two hour-postprandial plasma glucose (-39.2 mg/dL, -50.4 to -28.1); and daily total, basal, and bolus insulin dose (-8.99%, -10.93% to -7.05%; -8.03%, -10.14% to -5.93%; -9.14%, -12.17% to -6.12%; respectively). Sotagliflozin improved time in range (weighted mean difference 9.73%, 6.66% to 12.81%) and other continuous glucose monitoring parameters, and reduced body weight (-3.54%, -3.98% to -3.09%), systolic blood pressure (-3.85 mm Hg, -4.76 to -2.93), and albuminuria (albumin:creatinine ratio -14.57 mg/g, -26.87 to -2.28). Sotagliflozin reduced hypoglycaemia (weighted mean difference -9.09 events per patient year, -13.82 to -4.36) and severe hypoglycaemia (relative risk 0.69, 0.49 to 0.98). However, the drug increased the risk of ketoacidosis (relative risk 3.93, 1.94 to 7.96), genital tract infections (3.12, 2.14 to 4.54), diarrhoea (1.50, 1.08 to 2.10), and volume depletion events (2.19, 1.10 to 4.36). Initial HbA1c and basal insulin dose adjustment were associated with the risk of diabetic ketoacidosis. A sotagliflozin dose of 400 mg/day was associated with a greater improvement in most glycaemic and non-glycaemic outcomes than the 200 mg/day dose, without increasing the risk of adverse events. The quality of evidence was high to moderate for most outcomes, but low for major adverse cardiovascular events and all cause death. The relatively short duration of trials prevented assessment of long term outcomes.
CONCLUSIONS: In type 1 diabetes, sotagliflozin improves glycaemic and non-glycaemic outcomes and reduces hypoglycaemia rate and severe hypoglycaemia. The risk of diabetic ketoacidosis could be minimised by appropriate patient selection and down-titration of the basal insulin dose.
参考来源
- Musso G, Gambino R, Cassader M, et al. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2019. PMID: 30967375. doi:10.1136/bmj.l1328
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。